Literature DB >> 20842601

Meningococcal meningitis.

Ricardo G Branco1, Robert C Tasker.   

Abstract

OPINION STATEMENT: Meningococcal meningitis (MM) is the most common presentation of meningococcal disease and an important cause of morbidity and mortality worldwide. When MM is associated with shock, early recognition and treatment of shock is essential. No investigation should delay starting antibiotics once the diagnosis is suspected. Corticosteroids can be started at the same time as the antibiotics or just before, but this is not a specific recommendation for MM. Low-dose steroids should be used in meningococcal disease with refractory shock. Altered blood flow, cerebral edema, and raised intracranial pressure are problems that should be considered in all patients with MM and decreased consciousness level. When mechanical ventilation is required, the target carbon dioxide level is 4.0 to 4.5 kPa, with avoidance of hypocapnia. Seizures, although not frequent, can occur in MM and require prompt treatment. Other treatments, such as mannitol and activated protein C, should be avoided. Potential new treatments requiring further investigation include neuroprotection with hypothermia or glycerol.

Entities:  

Year:  2010        PMID: 20842601     DOI: 10.1007/s11940-010-0086-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  38 in total

Review 1.  Meningococcal disease.

Authors:  N E Rosenstein; B A Perkins; D S Stephens; T Popovic; J M Hughes
Journal:  N Engl J Med       Date:  2001-05-03       Impact factor: 91.245

2.  Regional cerebral blood flow, cerebral metabolic rate of oxygen, and cerebrospinal fluid acid-base variables in patients with acute meningitis and with acute encephalitis.

Authors:  O B Paulson; P Brodersen; E L Hansen; H S Kristensen
Journal:  Acta Med Scand       Date:  1974-09

Review 3.  The epidemiology of meningococcal disease and the impact of vaccines.

Authors:  Ameneh Khatami; Andrew J Pollard
Journal:  Expert Rev Vaccines       Date:  2010-03       Impact factor: 5.217

4.  Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit.

Authors:  Stephen J Gray; Caroline L Trotter; Mary E Ramsay; Malcolm Guiver; Andrew J Fox; Raymond Borrow; Richard H Mallard; Edward B Kaczmarski
Journal:  J Med Microbiol       Date:  2006-07       Impact factor: 2.472

Review 5.  Meningococcal disease and meningitis.

Authors:  Ricardo G Branco; Carolina F Amoretti; Robert C Tasker
Journal:  J Pediatr (Rio J)       Date:  2007-04-26       Impact factor: 2.197

6.  Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial.

Authors:  Heikki Peltola; Irmeli Roine; Josefina Fernández; Inés Zavala; Silvia González Ayala; Antonio González Mata; Antonio Arbo; Rosa Bologna; Greta Miño; José Goyo; Eduardo López; Solange Dourado de Andrade; Seppo Sarna
Journal:  Clin Infect Dis       Date:  2007-10-15       Impact factor: 9.079

Review 7.  Pre-admission antibiotics for suspected cases of meningococcal disease.

Authors:  T Sudarsanam; P Rupali; P Tharyan; O C Abraham; K Thomas
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 8.  Epidemic meningitis, meningococcaemia, and Neisseria meningitidis.

Authors:  David S Stephens; Brian Greenwood; Petter Brandtzaeg
Journal:  Lancet       Date:  2007-06-30       Impact factor: 79.321

9.  Social behavior and meningococcal carriage in British teenagers.

Authors:  Jenny MacLennan; George Kafatos; Keith Neal; Nick Andrews; J Claire Cameron; Richard Roberts; Meirion R Evans; Kathy Cann; David N Baxter; Martin C J Maiden; James M Stuart
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

10.  Drotrecogin alfa (activated) in patients with severe sepsis presenting with purpura fulminans, meningitis, or meningococcal disease: a retrospective analysis of patients enrolled in recent clinical studies.

Authors:  Jean-Louis Vincent; Simon Nadel; Demetrios J Kutsogiannis; R T Noel Gibney; S Betty Yan; Virginia L Wyss; Joan E Bailey; Carol L Mitchell; Samiha Sarwat; Stephen M Shinall; Jonathan M Janes
Journal:  Crit Care       Date:  2005-05-17       Impact factor: 9.097

View more
  5 in total

1.  Therapeutic hypothermia for adult viral meningoencephalitis.

Authors:  Marko Kutleša; Bruno Baršić; Dragan Lepur
Journal:  Neurocrit Care       Date:  2011-08       Impact factor: 3.210

2.  Concurrent meningococcal and herpes simplex infection in a non-immunocompromised child.

Authors:  Jasmin Ali; Hannah Walsh; Swathi Sanapala; Nadeem Syed
Journal:  BMJ Case Rep       Date:  2014-04-15

Review 3.  Meningococcal disease in childhood: epidemiology, clinical features and prevention.

Authors:  S Bosis; A Mayer; S Esposito
Journal:  J Prev Med Hyg       Date:  2015-08-31

4.  Rapid response to meningococcal disease cluster in Foya district, Lofa County, Liberia January to February 2018.

Authors:  Julius Monday Rude; Lavele Kortimai; Fallah Mosoka; Baller April; Mouhamoud Nuha; Victoria Katawera; Thomas Nagbe; Alpha Tamba; Williams Desmound; Richard Mulbah; Formenty Pierre; Emmanuel Musa Onuche; Joseph Okeibunor Chukwudi; Ambrose Talisuna; Ali Ahmed Yahaya; Soatiana Rajatonirina; Tolbert Nyenswah; Bernice Dahn; Alex Gasasira; Ibrahima Socé Fall
Journal:  Pan Afr Med J       Date:  2019-05-29

5.  Encephalitis hospitalization rates and inpatient mortality in the United States, 2000-2010.

Authors:  Benjamin P George; Eric B Schneider; Arun Venkatesan
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.